血必净改善急性百草枯中毒患者临床预后并降低死亡率:一项纳入1429例患者的Meta分析
该Meta分析纳入27项随机对照试验(26项中文、1项英文),共1429例急性百草枯中毒患者,其中试验组726例接受血必净注射液联合常规治疗,对照组703例仅接受常规治疗。作者认为血必净注射液可降低急性百草枯中毒患者死亡率,可能通过改善肝肾功能、减轻炎症和氧化应激损伤、抑制肺纤维化及提高氧合水平实现。漏斗图分析提示存在发表偏倚。
要点
- 血必净组14天ALT平均差为-78.35(95%CI -127.35~-29.34),7天SCr平均差为-135.13(95%CI -219.09~-51.17),14天SCr平均差为-206.05(95%CI -290.13~-121.96)。
- 血必净组CRP平均差为-11.55(95%CI -17.77~-5.33),TNF-α平均差为-9.27(95%CI -15.48~-3.96),MDA平均差为-1.27(95%CI -1.57~-0.96),SOD平均差为13.88(95%CI 7.43~20.33)。
- 漏斗图分析提示纳入超过10篇文献的参数存在发表偏倚。
适用人群与场景
- 急性百草枯中毒患者,纳入27项随机对照试验共1429例,其中试验组726例、对照组703例。
处置流程与药物剂量
- 试验组:血必净注射液联合常规治疗;对照组:仅常规治疗。原文未写明血必净注射液的剂量、给药途径、频次和疗程。
研究设计与关键结果
- 研究类型:Meta分析,纳入27项随机对照试验(26项中文、1项英文),共1429例急性百草枯中毒患者,试验组726例接受血必净注射液联合常规治疗,对照组703例仅接受常规治疗。
证据类型、等级与局限
- 证据类型:Meta分析,纳入27项随机对照试验(26项中文、1项英文),共1429例患者。
- 文献质量按Cochrane 5.1手册评价,原文未报告具体质量评价结果和证据等级。
- 局限:原文报告漏斗图分析提示存在发表偏倚。
对床旁实践的改变
- 作者认为血必净注射液可降低急性百草枯中毒患者死亡率,可能通过改善肝肾功能、减轻炎症和氧化应激损伤、抑制肺纤维化及提高氧合水平实现。
- 原文未据此给出具体的临床推荐意见。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
- 另有 10 条提炼内容因数值无法与原文逐一核对而未列出,请以原文为准。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore the therapeutic effect of Xuebijing on patients with acute paraquat poisoning (APP) by using systematic evaluation method.
METHODS: PubMed, Cochrane Library, Embase, Wanfang database, China National Knowledge Infrastructure (CNKI), VIP database (VIP) and China Biology Medicine (CBM) were searched using the computers to find the literatures published about the Xuebijing injection for the treatment of APP. Randomized controlled trials (RCT) were retrieved from the establishment of the database to August 2019. Patients in experimental group were treated with Xuebijing injection combined with conventional treatment, while the patients in control group were only given conventional treatment. The patients' outcome included the 14-day mortality, arterial oxygen saturation (SaO2) and incidence of pulmonary fibrosis. In addition, the 6-month survival rate, alanine aminotransferase (ALT), serum creatinine (SCr), C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), malondialdehyde (MDA) and superoxide dismutase (SOD) between the two groups were compared. The literature data were extracted by two researchers independently, and the quality of the literatures was evaluated according to the Cochrane 5.1 handbook. The Meta-analysis was performed by using RevMan 5.3 software. The results stability of Meta-analysis was tested by sensitivity analysis. The publication bias was analyzed through drawing of funnel diagram.
RESULTS: Twenty-seven RCT studies in total were enrolled, of which 26 were in Chinese and 1 was in English. A total of 1 429 patients were enrolled, among whom 726 were in experimental group and another 703 were in control group. Meta-analysis showed that compared with the control group, the 14-day mortality [relative risk (RR) = 0.62, 95% confidence interval (95%CI) was 0.54 to 0.72, P < 0.000 01] and incidence of pulmonary fibrosis (RR = 0.67, 95%CI was 0.53 to 0.85, P = 0.000 9) of patients in the experimental group were significantly lowered, while SaO2 at 7 days and 14 days were significantly increased [7 days: mean difference (MD) = 16.86, 95%CI was 9.89 to 23.83, P < 0.000 01; 14 days: MD = 16.51, 95%CI was 10.22 to 22.80, P < 0.000 01]. Compared with the control group, the survival rate within 6 months (RR = 1.55, 95%CI was 1.41 to 1.71, P < 0.000 01) and SOD (MD = 13.88, 95%CI was 7.43 to 20.33, P < 0.000 1) of patients in the experimental group were significantly increased, ALT at 14 days (MD = -78.35, 95%CI was -127.35 to -29.34, P = 0.000 5), SCr at 7 days and 14 days (7 days: MD = -135.13, 95%CI was -219.09 to -51.17, P = 0.002; 14 days: MD = -206.05, 95%CI = -290.13 to -121.96, P < 0.000 01), CRP (MD = -11.55, 95%CI was -17.77 to -5.33, P = 0.000 3), TNF-α (MD = -9.27, 95%CI was -15.48 to -3.96, P = 0.000 9) and MDA (MD = -1.27, 95%CI was -1.57 to -0.96, P < 0.000 01) were significantly lowered. The overall effect value of the parameters with high heterogeneity was not significantly changed after further Meta-analysis excluding any one of the studies, suggesting that the result was relatively stable. Funnel chart analysis was used to analyze the parameters from more than 10 articles enrolled, and it showed that there was publication bias.
CONCLUSIONS: Xuebijing injection can reduce the mortality of patients with APP, which may because that it can improve liver and kidney function, reduce inflammation and oxidative stress damage, inhibit pulmonary fibrosis and increase oxygenation level.
参考来源
- Qian H, Liu B, Shen F, et al. [Xuebijing improves clinical prognosis and reduces mortality in patients with acute paraquat poisoning: a Meta-analysis included 1 429 patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 31898576. doi:10.3760/cma.j.issn.2095-4352.2019.11.020
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。